Kane Biotech Inc. (CVE:KNE – Get Free Report) reached a new 52-week low during mid-day trading on Thursday . The company traded as low as C$0.09 and last traded at C$0.09, with a volume of 11000 shares. The stock had previously closed at C$0.10.
Kane Biotech Stock Down 5.3 %
The firm’s fifty day moving average is C$0.10 and its 200 day moving average is C$0.11. The company has a debt-to-equity ratio of -331.42, a quick ratio of 0.39 and a current ratio of 0.80. The firm has a market cap of C$12.97 million, a P/E ratio of 2.25 and a beta of 0.52.
Insider Activity at Kane Biotech
In related news, Director Marc Edwards purchased 2,000,000 shares of Kane Biotech stock in a transaction that occurred on Friday, January 17th. The shares were acquired at an average price of C$0.10 per share, with a total value of C$200,000.00. 37.21% of the stock is currently owned by corporate insiders.
About Kane Biotech
Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections.
Featured Articles
- Five stocks we like better than Kane Biotech
- What Do S&P 500 Stocks Tell Investors About the Market?
- MarketBeat Week in Review – 03/24 – 03/28
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low
- How to Invest in the Best Canadian Stocks
- 4 Healthcare Stocks With Massive Gains—and More to Come
Receive News & Ratings for Kane Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kane Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
